Effectiveness of natriuretic peptide-guided treatment of chronic heart failure. A meta-analysis

被引:2
|
作者
Gamino-Arroyo, Ana-Estela [1 ]
Prado-Galbarro, Francisco-Javier [2 ,3 ,4 ]
Garcia-Perez, Sonia [4 ,5 ]
Sanchez-Piedra, Carlos [4 ]
机构
[1] Hosp Infantil Mexico Dr Federico Gomez, Unidad Infectol, Ciudad De Mexico, Mexico
[2] Inst Nacl Enfermedades Resp, Ctr Invest Enfermedades Infecciosas, Ciudad De Mexico, Mexico
[3] Inst Nacl Salud Publ, Unidad Salud Reprod, Cuernavaca, Morelos, Mexico
[4] Inst Salud Carlos III, Agencia Evaluac Tecnol Sanitarias, Madrid, Spain
[5] REDISSEC, Unidad Invest, Madrid, Spain
来源
ARCHIVOS DE CARDIOLOGIA DE MEXICO | 2018年 / 88卷 / 03期
关键词
Heart failure; Natriuretic peptide; Meta-analysis; Therapy; NT-proBNP; Mexico;
D O I
10.1016/j.acmx.2017.02.008
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Objective: To evaluate the efficacy of natriuretic peptide (NP)-guided therapy compared to clinically-guided therapy in reducing mortality and hospital admissions in chronic heart failure (HF) patients. Methods: Randomised clinical trials (RCT) were selected through a systematic review. Four meta-analyses were conducted for the outcomes of overall mortality, HF-related mortality, overall hospital admissions, and HF-related hospital admissions. Heterogeneity between studies and publication bias were also assessed. Results: Nine RCTs were found with a total of 1914 patients. NP-guided therapy significantly reduced overall mortality and HF-related hospital admissions. No significant results were found for HF-related mortality and overall hospital admissions. Some clinical heterogeneity regarding interventions performed was found between studies. Publication bias was found for HF-related and overall hospital admissions. Conclusions: NP-guided therapy seems to improve outcomes compared to clinically-guided therapy. However, heterogeneity found between interventions might reduce the generalisation of these results. Specific interventions of the clinical trials should be examined when making recommendations regarding NP-guided therapy. (C) 2017 Instituto Nacional de Cardiologia Ignacio Chavez. Published by Masson Doyma Mexico S.A.
引用
收藏
页码:171 / 177
页数:7
相关论文
共 50 条
  • [31] Natriuretic Peptide-Guided Heart Failure Therapy After the GUIDE-IT Study
    Januzzi, James L., Jr.
    Richards, A. Mark
    CIRCULATION, 2018, 137 (20) : 2101 - 2103
  • [32] Natriuretic peptide-guided levosimendan therapy for heart failure: A promising new approach
    Giamouzis, Grigorios
    Giannakoulas, Georgios
    Tsarpalis, Konstantinos
    Agha, Syed A.
    Georgiopoulou, Vasiliki
    Kalogeropoulos, Andreas
    Karvounis, Haralambos
    Butler, Javed
    INTERNATIONAL JOURNAL OF CARDIOLOGY, 2008, 128 (01) : 91 - 93
  • [33] Changes of natriuretic peptides predict hospital admissions in patients with chronic heart failure. A meta-analysis
    Savarese, G.
    Musella, F.
    D'amore, C.
    Vassallo, E.
    Losco, T.
    Gambardella, F.
    Cecere, M.
    Petraglia, L.
    Trimarco, B.
    Filardi, P. Perrone
    EUROPEAN HEART JOURNAL, 2014, 35 : 1180 - 1181
  • [34] Natriuretic Peptide-Guided Therapy in Chronic Heart Failure: A Meta-Analysis of 2,686 Patients in 12 Randomized Trials (vol 8, e58287, 2013)
    Savarese, G.
    Trimarco, B.
    Dellegrottaglie, S.
    Prastaro, M.
    Gambardella, F.
    PLOS ONE, 2014, 9 (04):
  • [35] Model-based cost-effectiveness analysis of B-type natriuretic peptide-guided care in patients with heart failure
    Mohiuddin, Syed
    Reeves, Barnaby
    Pufulete, Maria
    Maishman, Rachel
    Dayer, Mark
    Macleod, John
    McDonagh, Theresa
    Purdy, Sarah
    Rogers, Chris
    Hollingworth, William
    BMJ OPEN, 2016, 6 (12):
  • [36] Natriuretic peptide-guided management of patients with heart failure: a decade of progress but still a controversy
    Baibars, Motaz
    Ibrahim, Ahmed
    Fang, James C.
    Sipahi, Ilke
    FUTURE CARDIOLOGY, 2010, 6 (06) : 743 - 747
  • [37] Economic and Quality-of-Life Outcomes of Natriuretic Peptide-Guided Therapy for Heart Failure
    Mark, Daniel B.
    Cowper, Patricia A.
    Anstrom, Kevin J.
    Sheng, Shubin
    Daniels, Melanie R.
    Knight, J. David
    Baloch, Khaula N.
    Davidson-Ray, Linda
    Fiuzat, Mona
    Januzzi, James L., Jr.
    Whellan, David J.
    Pina, Ileana L.
    Ezekowitz, Justin A.
    Adams, Kirkwood F.
    Cooper, Lawton S.
    O'Connor, Christopher M.
    Felker, G. Michael
    JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY, 2018, 72 (21) : 2551 - 2562
  • [38] Cost-effectiveness of B-type natriuretic peptide-guided care in patients with heart failure: a systematic review
    Jafari, Abdosaleh
    Rezapour, Aziz
    Hajahmadi, Marjan
    HEART FAILURE REVIEWS, 2018, 23 (05) : 693 - 700
  • [39] Cost-effectiveness of B-type natriuretic peptide-guided care in patients with heart failure: a systematic review
    Abdosaleh Jafari
    Aziz Rezapour
    Marjan Hajahmadi
    Heart Failure Reviews, 2018, 23 : 693 - 700
  • [40] Natriuretic peptide-guided therapy reduces mortality more than clinically guided therapy in heart failure
    Van Spall, Harriette G. C.
    ANNALS OF INTERNAL MEDICINE, 2014, 161 (04)